Sara Moufarrij

Sara Moufarrij


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
SMSara Moufarrij
Sara Moufarrij
RORoisin O'cearbhaill
Roisin O'cearbhaill
Despite high response rates to initial therapy, most patients with ovarian cancer will ultimately recur and go on to develop resistance to standard treatments. Novel therapies have been developed to overcome drug resistance and alter the tumor immune microenvironment by targeting oncogenic pathways, activating the innate immune response, and enhancing drug delivery. In this review, we discuss the current and future roles of chemotherapy, targeted agents such as poly (ADP-ribose) polymerase (PARP) inhibitors, bevacizumab, and mirvetuximab in the treatment of ovarian cancer. We explore the emerging role of therapeutic targets, including DNA repair pathway inhibitors and novel antibody–drug conjugates. Furthermore, we delve into the role of immunotherapeutic agents such as interleukins as well as immune-promoting agents such as oncolytic viruses and cancer vaccines. Innovative combination therapies using these agents have led to a rapidly evolving treatment landscape and promising results for patients with recurrent ovarian cancer.

6 November 2024 in Gynecologic Oncology
Verified
Journal Article
Closed access
SMSara Moufarrij
Sara Moufarrij
YLYulia Lakhman
Yulia Lakhman
CACarol Aghajanian
Carol Aghajanian
NANadeem Abu-Rustum
Nadeem Abu-Rustum
LELora H. Ellenson
Lora H. Ellenson
AMAmir Momeni-Boroujeni
Amir Momeni-Boroujeni

22 October 2024 in Gynecologic Oncology
Verified
Journal Article
Closed access
SMSara Moufarrij
Sara Moufarrij
CDChristian Dagher
Christian Dagher
OFOlga T. Filippova
Olga T. Filippova
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
YSYukio Sonoda
Yukio Sonoda